

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1 (currently amended): A method for treating unwanted ocular neovascularity in a subject suffering from choroidal neovascularization or retinal neovascularization, the method comprising;

(a) administering an effective amount of an anti-angiogenic agent to the subject, wherein the anti-angiogenic agent is selected from the group consisting of inhibitors of protein kinase C, antagonists of growth hormone, antagonists of IGF-1, antagonists of vascular endothelial growth factor, [inhibitors of cyclooxygenase II], antagonists of angiotensin II, antagonists of NF-kappa B, and phospholipase A2 antagonists;

(b) administering an effective amount of a photosensitive agent to the subject; and

(c) irradiating the unwanted neovascularity with light having a wavelength absorbable by the photosensitive agent.

Claim 2 (original): The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks before the administration of the photosensitive agent.

Claim 3 (original): The method of claim 1, wherein the anti-angiogenic agent and the photosensitive agent are administered simultaneously.

Claim 4 (original): The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks after the administration of the photosensitive agent.

Claim 5 (original): The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks before the administration of the photosensitive agent and between about 0 and about 4 weeks after the administration of the photosensitive agent.

Claim 6 (cancelled)

Claim 7 (previously presented): The method of claim 1, wherein the anti-angiogenic agent is selected from the group consisting of inhibitors of protein kinase C and antagonists of vascular endothelial growth factor.

Claim 8 (original): The method of claim 7, wherein the anti-angiogenic agent is an inhibitor of protein kinase C.

Claim 9 (original): The method of claim 7, wherein the anti-angiogenic agent is selected from the group consisting of N-benzoyl-staurosporine, CGP 79787, and octreotide.

Claim 10 (original): The method of claim 9, wherein the anti-angiogenic agent is N-benzoyl-staurosporine.

Claim 11 (original): The method of claim 1, wherein the photosensitive agent is selected from the group consisting of a porphyrin and a purpurin.

Claim 12 (original): The method of claim 11, wherein the photosensitive agent is benzoporphyrin derivative monacid ring A.

Claim 13 (original): The method of claim 2, wherein multiple administrations of anti-angiogenic agent are performed prior to the administration of the photosensitive agent.

Claim 14 (original): The method of claim 4, wherein multiple administrations of anti-angiogenic agent are performed after the administration of the photosensitive agent.

Claim 15 (original): The method of claim 5, wherein multiple administrations of anti-angiogenic agent are performed prior to the administration of the photosensitive agent and wherein multiple administrations of anti-angiogenic agent are performed after the administration of the photosensitive agent.

Claims 16-19 (cancelled)

Claim 20 (previously presented): The method of claim 9, wherein the anti-angiogenic agent is CGP 79787.

Claim 21 (new): The method of claim 9, wherein the anti-angiogenic agent is octreotide.